Research Repository

Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer

Reebye, V and Cano, LQ and Lavery, DN and Brooke, GN and Powell, SM and Chotai, D and Walker, MM and Whitaker, HC and Wait, R and Hurst, HC and Bevan, CL (2012) 'Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer.' Molecular Endocrinology, 26 (10). 1694 - 1706. ISSN 0888-8809

[img]
Preview
Text
1694.full.pdf - Published Version

Download (1MB) | Preview
[img]
Preview
Text (Supplemental Data)
me-12-1056_F5_T1_Supplemental_data_revised.pdf

Download (770kB) | Preview

Abstract

Prostate tumor growth initially depends on androgens, which act via the androgen receptor (AR). Despite androgen ablation therapy, tumors eventually progress to a castrate-resistant stage in which the AR remains active. The mechanisms are poorly understood but it may be that changes in levels or activity of AR coregulators affect trafficking and activation of the receptor. A key stage in AR signaling occurs in the cytoplasm, where unliganded receptor is associated with the heat shock protein (HSP)90 foldosome complex. p23, a key component of this complex, is best characterized as a cochaperone for HSP90 but also has HSP90-independent activity and has been re-ported as having differential effects on the activity of different steroid receptors. Here we report that p23 increases activity of the AR, and this appears to involve steps both in the cytoplasm (increasing ligand-binding capacity, possibly via direct interaction with AR) and the nucleus (en-hancing AR occupancy at target promoters). We show, for the first time, that AR and p23 can interact, perhaps directly, when HSP90 is not present in the same complex. The effects of p23 on AR activity are at least partly HSP90 independent because a mutant form of p23, unable to bind HSP90, nevertheless increases AR activity. In human prostate tumors, nuclear p23 was higher in malignant prostate cells compared with benign/normal cells, supporting the utility of p23 as a therapeutic target in prostate cancer. © 2012 by The Endocrine Society.

Item Type: Article
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculty of Science and Health > Life Sciences, School of
Depositing User: Jim Jamieson
Date Deposited: 27 Nov 2013 12:24
Last Modified: 16 Sep 2019 10:15
URI: http://repository.essex.ac.uk/id/eprint/8300

Actions (login required)

View Item View Item